marketcap
Facebook
X
TelegramAnnual report 2022
added 03-30-2023
HTG Molecular Diagnostics Financial Ratios 2011-2025 | HTGM
Annual Financial Ratios HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -0.1 | -1.4 | -1.1 | -3.6 | -2.1 | -0.5 | -0.7 | - | - | - | - |
P/S |
0.5 | 0.2 | 3.5 | 1.1 | 2.7 | 2.7 | 2.5 | 3.5 | - | - | - | - |
EPS |
-24.3 | -29.7 | -4.5 | -7.6 | -0.6 | -1.8 | -3.7 | -5.0 | -175.0 | - | - | - |
EV (Enterprise Value) |
3.16 M | 12.1 M | 28.2 M | 34.9 M | 72.9 M | 54.5 M | 29.3 M | 33.2 M | 29.2 M | 26.8 M | 26.7 M | - |
EBITDA per Share |
-22.8 | -29.6 | -3.94 | -6.78 | -8.01 | -23.3 | -48.2 | -60.5 | - | - | - | - |
EV/EBITDA |
-1.4 | -1.0 | -1.4 | -4.1 | -2.4 | -0.7 | -1.2 | - | - | - | - | |
PEG |
-0.0 | -0.0 | 0.03 | 0.07 | 0.05 | 0.04 | 0.02 | 0.01 | - | - | - | - |
P/B |
0.6 | 0.2 | 2.1 | 0.9 | 2.8 | -13.1 | -2.3 | 0.8 | - | - | - | - |
P/CF |
-0.2 | -0.1 | -1.8 | -1.2 | -4.2 | -2.3 | -0.5 | -0.7 | - | - | - | - |
ROE % |
-400.51 | -164.86 | -144.08 | -80.51 | -78.01 | 619.70 | 465.59 | -126.66 | - | - | - | - |
ROA % |
-121.47 | -56.29 | -59.29 | -42.77 | -37.59 | -89.20 | -141.10 | -54.24 | - | - | - | - |
ROCE % |
-219.45 | -171.39 | -70.04 | -52.35 | -43.97 | -223.93 | -288.52 | -57.02 | - | - | - | - |
Current Ratio |
1.4 | 1.5 | 4.5 | 4.6 | 5.4 | 1.3 | 1.5 | 5.5 | - | - | - | - |
DSO |
100.7 | 75.4 | 67.8 | 60.1 | 85.1 | 157.2 | 98.0 | 64.7 | - | - | - | - |
DIO |
115.6 | 155.1 | 136.4 | 52.0 | 93.7 | 86.7 | 133.4 | 240.9 | - | - | - | - |
DPO |
112.0 | 133.6 | 123.3 | 68.1 | 132.6 | 179.0 | 67.2 | 79.3 | - | - | - | - |
Operating Cycle |
216.4 | 230.5 | 204.3 | 112.1 | 178.8 | 243.9 | 231.3 | 305.6 | - | - | - | - |
Cash Conversion Cycle |
104.3 | 96.9 | 80.9 | 44.0 | 46.1 | 64.8 | 164.1 | 226.3 | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.41 | -0.54 | -0.81 | - | -0.6 | -0.39 | -0.8 | - | -1.12 | -1.3 | -1.27 | - | -0.15 | -0.17 | -0.19 | - | -0.17 | -0.14 | -0.22 | - | -0.46 | -0.6 | -0.73 | - | -0.92 | -0.98 | -1.02 | - | -0.76 | -1.73 | -14.99 | - | -44.14 | -49.62 | -37.8 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -0.38 | -0.5 | -0.76 | - | -0.54 | -0.58 | -0.73 | - | -1.01 | -1.05 | -1.17 | - | -0.14 | -0.15 | -0.18 | - | -0.16 | -0.13 | -0.2 | - | -0.41 | -0.53 | -0.64 | - | -0.81 | -0.85 | -0.92 | - | -0.68 | -1.15 | -11.5 | - | -28.7 | -34.6 | -27.3 | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-537.12 | -567.28 | -223.71 | -132.17 | -73.13 | -110.50 | -117.69 | -142.94 | -114.47 | -134.24 | -116.66 | -97.25 | -62.20 | -85.16 | -88.35 | -87.78 | -67.92 | 107.95 | 306.78 | 517.14 | 556.88 | 672.90 | 613.04 | 544.64 | 364.15 | 333.62 | 187.08 | 26.38 | -92.92 | -88.18 | -52.90 | -9.42 | 14.09 | 14.09 | 9.35 | 4.06 | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-82.53 | -95.54 | -75.37 | -55.86 | -33.26 | -48.63 | -50.99 | -60.21 | -47.11 | -57.61 | -52.74 | -47.15 | -33.04 | -44.11 | -44.67 | -43.41 | -32.73 | -58.04 | -72.29 | -90.40 | -80.16 | -115.31 | -125.16 | -134.81 | -110.36 | -123.45 | -101.39 | -80.64 | -39.85 | -77.74 | -102.54 | -128.38 | -112.51 | -112.51 | -74.61 | -32.40 | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-142.22 | -158.25 | -110.42 | -76.93 | -45.74 | -63.58 | -65.39 | -86.37 | -89.58 | -108.86 | -110.30 | -87.70 | -53.39 | -76.17 | -79.67 | -87.01 | -66.82 | 99.95 | 289.49 | 488.80 | 524.28 | 632.61 | 574.17 | 507.87 | 341.26 | 312.70 | 175.81 | 34.10 | -80.19 | -75.69 | -42.62 | -9.53 | 13.58 | 13.58 | 9.08 | 3.95 | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | 1.1 | 1.3 | 1.7 | 1.5 | 1.8 | 2.0 | 1.9 | 1.7 | 1.7 | 1.7 | 1.7 | 2.1 | 2.1 | 2.1 | 2.1 | 1.9 | 1.9 | 1.9 | 1.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 0.8 | 0.8 | 1.8 | 1.8 | 1.8 | 1.8 | 0.4 | 0.4 | 0.4 | 0.4 | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | 81.0 | 61.4 | 109.5 | - | 60.2 | 58.8 | 90.2 | - | 81.6 | 73.8 | 97.4 | - | 53.4 | 49.8 | 116.5 | - | 97.2 | 93.1 | 124.7 | - | 155.8 | 329.4 | 257.3 | - | 137.5 | 66.3 | 110.4 | - | 64.7 | 82.7 | 67.6 | - | 84.0 | 218.6 | 44.2 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | 248.0 | 178.9 | 214.0 | - | 216.1 | 184.2 | 179.8 | - | 144.7 | 139.7 | 124.1 | - | 39.4 | 46.2 | 57.5 | - | 96.2 | 82.2 | 99.8 | - | 98.9 | 87.1 | 94.8 | - | 122.6 | 147.8 | 200.8 | - | 248.3 | 240.6 | 198.2 | - | 205.8 | 249.9 | 119.7 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | 124.4 | 109.6 | 158.3 | - | 131.2 | 142.6 | 157.0 | - | 130.8 | 126.3 | 135.3 | - | 51.6 | 60.5 | 78.3 | - | 136.2 | 116.4 | 172.1 | - | 204.4 | 179.9 | 112.7 | - | 61.8 | 74.5 | 80.4 | - | 81.8 | 79.2 | 85.3 | - | 115.8 | 140.6 | 67.4 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 328.9 | 240.4 | 323.4 | - | 276.3 | 243.0 | 270.1 | - | 226.3 | 213.5 | 221.5 | - | 92.8 | 96.0 | 173.9 | - | 193.4 | 175.3 | 224.5 | - | 254.7 | 416.5 | 352.1 | - | 260.1 | 214.1 | 311.2 | - | 312.9 | 323.2 | 265.8 | - | 289.8 | 468.5 | 163.9 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 204.5 | 130.8 | 165.2 | - | 145.1 | 100.4 | 113.1 | - | 95.5 | 87.3 | 86.2 | - | 41.2 | 35.5 | 95.6 | - | 57.2 | 59.0 | 52.4 | - | 50.3 | 236.6 | 239.4 | - | 198.3 | 139.6 | 230.8 | - | 231.2 | 244.0 | 180.5 | - | 174.0 | 327.9 | 96.6 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company HTG Molecular Diagnostics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
$ 0.33 | -6.23 % | $ 30.6 M |  Germany |
 |
Fluidigm Corporation
FLDM
|
$ 3.75 | 1.08 % | $ 308 M |  USA |
 |
Global Cord Blood Corporation
CO
|
$ 2.99 | - | $ 399 M |  China |
 |
Oxford Immunotec Global PLC
OXFD
|
$ 21.99 | - | $ 562 M |  Britain |
 |
Genetron Holdings Limited
GTH
|
$ 4.03 | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
$ 0.46 | 0.22 % | $ 16.8 M | USA |
 |
Meridian Bioscience
VIVO
|
$ 33.97 | - | $ 1.49 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.04 | -9.15 % | $ 517 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 28.02 | 3.05 % | $ 20 B |  Niderland |
 |
Quotient Limited
QTNT
|
$ 0.32 | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quidel Corporation
QDEL
|
$ 27.31 | -1.44 % | $ 1.15 B | USA |
 |
Bioventus
BVS
|
$ 7.55 | 15.09 % | $ 473 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
$ 165.21 | - | $ 10.7 B | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 565.36 | 0.07 % | $ 216 B | USA |
 |
Heska Corporation
HSKA
|
$ 119.99 | - | $ 1.31 B | USA |
 |
Trinity Biotech plc
TRIB
|
$ 1.01 | 2.98 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 30.23 | -4.24 % | $ 1.75 B | USA |
 |
Motus GI Holdings
MOTS
|
$ 0.17 | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
$ 0.43 | -13.05 % | $ 7.29 M | USA |
 |
Syneos Health
SYNH
|
$ 42.98 | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
$ 0.09 | - | $ 21.2 M | USA |
 |
DermTech
DMTK
|
$ 0.09 | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
$ 0.29 | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
$ 31.25 | 20.24 % | $ 868 M | USA |
 |
DarioHealth Corp.
DRIO
|
$ 13.47 | -1.97 % | $ 382 M | Israel |
 |
PerkinElmer
PKI
|
$ 115.24 | -0.91 % | $ 14.7 B | USA |
 |
OpGen
OPGN
|
$ 1.96 | -16.95 % | $ 1.54 M | USA |
 |
DexCom
DXCM
|
$ 60.96 | 0.88 % | $ 23.5 B | USA |
 |
Organovo Holdings
ONVO
|
$ 2.12 | -2.3 % | $ 19.4 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 11.65 | -4.98 % | $ 125 M | China |
 |
Danaher Corporation
DHR
|
$ 214.35 | 0.12 % | $ 157 B | USA |
 |
Neogen Corporation
NEOG
|
$ 6.05 | -3.9 % | $ 1.31 B | USA |
 |
Biomerica
BMRA
|
$ 2.51 | -6.47 % | $ 5.77 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 22.72 | -1.69 % | $ 687 M | USA |
 |
Psychemedics Corporation
PMD
|
$ 2.67 | -1.84 % | $ 15.3 M | USA |
 |
Genetic Technologies Limited
GENE
|
$ 0.77 | - | $ 7.1 B |  Australia |
 |
Renalytix AI plc
RNLX
|
$ 0.21 | 5.66 % | $ 22.7 M | Britain |
 |
Myriad Genetics
MYGN
|
$ 6.56 | -19.8 % | $ 594 M | USA |
 |
Medpace Holdings
MEDP
|
$ 596.89 | 0.48 % | $ 18.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 211.79 | -1.0 % | $ 38.4 B | USA |
 |
CareDx, Inc
CDNA
|
$ 14.33 | -3.01 % | $ 770 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 16.72 | -3.8 % | $ 99.4 M | Israel |
|
Biodesix
BDSX
|
$ 7.52 | 18.53 % | $ 975 M | USA |
 |
T2 Biosystems
TTOO
|
$ 0.12 | -39.35 % | $ 313 K | USA |
 |
OPKO Health
OPK
|
$ 1.4 | -0.36 % | $ 972 M | USA |
 |
Guardant Health
GH
|
$ 98.81 | -0.12 % | $ 12.1 B | USA |
 |
Agilent Technologies
A
|
$ 146.82 | 1.47 % | $ 44.6 B | USA |
 |
Co-Diagnostics
CODX
|
$ 0.39 | -3.37 % | $ 11.4 M | USA |
 |
Lantheus Holdings
LNTH
|
$ 57.99 | 2.06 % | $ 4.01 B | USA |